Zachary Roberts - 02 Feb 2026 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Reporting relationship: EVP of R&D
Issuer ticker: ALLO
Reported as of: 02 Feb 2026
Net transaction value: -$63,189
SEC form: 4
Accepted by SEC: 04 Feb 2026, 17:07:38 UTC
Prior SEC filing: 23 Jan 2026
Next SEC filing: 06 Jul 2026
Source filing: View source filing
Reporting owner signature: /s/Earl Douglas, Attorney-in-Fact

Key filing fact

Zachary Roberts filed Form 4 for Allogene Therapeutics, Inc. (ALLO) on 04 Feb 2026.

Key facts

This page summarizes Zachary Roberts's Form 4 filing for Allogene Therapeutics, Inc. (ALLO).
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 04 Feb 2026, 17:07.

Change

Previous filing in this sequence was filed on 23 Jan 2026.
Current net transaction value: -$63,189.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001851044 Primary reporting owner

Roberts Zachary

Relationship: EVP of R&D
Address: 210 EAST GRAND AVE, SOUTH SAN FRANCISCO
Signature: /s/Earl Douglas, Attorney-in-Fact
Signature date: 04 Feb 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ALLO transaction

Common Stock

Sale

Transaction value: $63,189
Shares: -35,700
Change %: -5.8%
Price: $1.77
Shares after: 581,166
Date: 02 Feb 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ALLO transaction Derivative

Stock Option (Right to buy)

Award

Transaction value: $0
Shares: +718,763
Change %
Price: $0.000000
Shares after: 718,763
Date: 02 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 718,763
Exercise price: $1.87
Footnotes: F3

ALLO transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +203,307
Change %
Price: $0.000000
Shares after: 203,307
Date: 02 Feb 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 203,307
Exercise price
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

Footnote F2

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.87, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.

Footnote F3

25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.

Footnote F4

Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date.